Canada Gazette, Part I, Volume 160, Number 47: GOVERNMENT NOTICES

November 21, 2026

BANK OF CANADA

PAYMENT CLEARING AND SETTLEMENT ACT

Notice of designation to the Canadian Payments Association

Under subsection 4(1) of the Payment Clearing and Settlement Act (the “Act”), if the Governor of the Bank of Canada is of the opinion that a clearing and settlement system could be operated in a manner that poses a systemic risk or payments system risk, and the Minister of Finance is of the opinion that it is in the public interest to do so, the Governor may designate the system as a clearing and settlement system that is subject to Part I of the Act.

The Real-Time Rail (RTR) is eligible to be designated under the Act, as the RTR has at least three participants, including at least one Canadian participant and at least one participant whose head office is located outside Ontario, where the head office of the Canadian Payments Association (Payments Canada) is located; clearing and settlement are conducted in Canadian dollars; and payment obligations that arise from the system are ultimately settled through adjustments to participants’ accounts at the Bank of Canada.

Payments Canada operates the RTR, which will provide continuous clearing and settlement of payments with immediate availability of funds. The RTR will serve as the clearing and settlement system for Interac e-Transfer, a prominent payment system. Given the role of the RTR in supporting widely used payment services, a disruption to or failure of the RTR could impair the ability of individuals and businesses to make payments and could adversely affect confidence in the Canadian payments system.

I am of the opinion that the RTR could be operated in such a manner as to pose a payments system risk and, therefore, should be designated as subject to Part I of the Act. The Minister of Finance is of the opinion that it would be in the public interest to designate the RTR.

Accordingly, the RTR is hereby designated pursuant to subsection 4(1) of the Act, effective November 8, 2026.

November 8, 2026

Tiff Macklem
Governor

DEPARTMENT OF FINANCE

CONSUMER-DRIVEN BANKING ACT

Financial Data Exchange Inc. — Designation of the technical standards body

Whereas, before designating the technical standards body referred to in subsection 125(1) of the Consumer-Driven Banking Act, the Minister of Finance took into account the factors set out in paragraphs 125(2)(a) to (e) of that Act;

And whereas the Minister of Finance, under paragraph 125(2)(f) of that Act, considered it relevant to also take into account

Therefore, the Minister of Finance, under subsection 125(1) of the Consumer-Driven Banking Act, designates Financial Data Exchange Inc. acting through its FDX Canada Council, to be the technical standards body that is responsible for establishing the technical standard that is to be used for the sharing of data by participating entities in accordance with that Act.

Ottawa, November 13, 2026

François-Philippe Champagne
Minister of Finance

DEPARTMENT OF FINANCE

CONSUMER-DRIVEN BANKING ACT

Ombudsman for Banking Services and Investments — Designation of the external complaints body

Whereas, before designating a corporation to be the external complaints body referred to in subsection 114(1) of the Consumer-Driven Banking Act, the Minister of Finance took into account all factors that the Minister considers relevant, including those set out in subsection 114(2) of that Act;

Therefore, the Minister of Finance, on the recommendation of the Bank of Canada, under subsection 114(1) of the Consumer-Driven Banking Act, designates the Ombudsman for Banking Services and Investments, a corporation incorporated under the Canada Not-for-profit Corporations Act, to be the external complaints body referred to in subsection 114(1) of the Consumer-Driven Banking Act.

Ottawa, November 13, 2026

François-Philippe Champagne
Minister of Finance

DEPARTMENT OF HEALTH

DEPARTMENT OF HEALTH ACT

Notice of annual increase of Health Canada’s Drug Master Files and Certificate of Pharmaceutical Product fees

Notice is hereby given that the Minister of Health, under the Ministerial Authority to Enter into Contract, updates the fees that are payable for the provision of Drug Master Files and Certificate of Pharmaceutical Product services by 2%, rounded up to the nearest dollar.

The current fees and the fees updated as of April 1, 2027, are listed below.

Any inquiries or comments about the updated fees can be directed to Rosslynn Miller-Lee, Director General, Business Facilitation and Modernization Directorate, Health Products and Food Branch, 613‑327‑0798 (telephone) or cro-brc@hc-sc.gc.ca (email).

Table: Annual increase of Drug Master Files and Certificate of Pharmaceutical Product fees
Services Fee as of April 1, 2026 Fee as of April 1, 2027
Certificate of Pharmaceutical Product (or a supplemental copy of a Certificate of Pharmaceutical Product) $105 $108
New Master Files (file registration) $1,436 $1,465
Drug Master Files — letter of access $204 $209
Drug Master Files — update $624 $637

DEPARTMENT OF HEALTH

FINANCIAL ADMINISTRATION ACT

Notice of annual adjustment of fees for dealer’s licences

Notice is hereby given, under section 19.2 of the Financial Administration Act, that in keeping with section 4 of the Fees in Respect of Dealer’s Licences Regulations, the fee for dealer’s licences: human drugs will increase by the annual 2% amount, rounded up to the nearest dollar. Under subsection 17(1) of the Service Fees Act (a fee is adjusted in each fiscal year — on the anniversary of a date that is selected by the responsible authority with respect to the fee before the first adjustment — by the percentage change over 12 months in the April All-items Consumer Price Index [CPI] for Canada, as published by Statistics Canada under the Statistics Act, for the previous fiscal year), the dealer’s licence: veterinary drugs (as per the Licensed Dealers for Controlled Drugs and Narcotics (Veterinary Use) Fees Regulations) will be adjusted by the CPI. Health Canada has chosen April 1 as the anniversary date. The CPI for this year is 2.8%.

The current fees and the fees updated as of April 1, 2027, are listed below.

Any inquiries or comments about the updated fees can be directed to Rosslynn Miller-Lee, Director General, Business Facilitation and Modernization Directorate, Health Products and Food Branch, 613‑327‑0798 (telephone) or cro-brc@hc-sc.gc.ca (email).

Table: Annual adjustment of fees for dealer’s licences
Type of licence Fee as of April 1, 2026 Fee as of April 1, 2027
Dealer’s licence (human drugs) $6,078 $6,200
Dealer’s licence (veterinary drugs) $2,192.31 $2,253.69
Dealer’s licence (veterinary drugs, first year) $1,096.16 $1,126.85

DEPARTMENT OF HEALTH

FOOD AND DRUGS ACT

Notice of annual adjustment of the Fees in Respect of Drugs and Medical Devices Order

Notice is hereby given, under subsection 30.61(1) of the Food and Drugs Act, that in keeping with section 4.1 of the 2020 Fees in Respect of Drugs and Medical Devices Order, every fee outlined in the Order is to be adjusted annually based on the Consumer Price Index (CPI), rounded up to the nearest dollar. The CPI is calculated based on the percentage change over 12 months in the April All-items CPI for Canada, as published by Statistics Canada under the Statistics Act, for the previous fiscal year. The CPI for this year is 2.8%.

The current fees and the fees updated as of April 1, 2027, are listed below.

Any inquiries or comments about the updated fees can be directed to Rosslynn Miller-Lee, Director General, Business Facilitation and Modernization Directorate, Health Products and Food Branch, 613‑327‑0798 (telephone) or cro-brc@hc-sc.gc.ca (email).

Human Drug Submission Review

Part 2 — Drugs

Table 1: Fees for examination of a submission — drugs for human use (Schedule 1)
Section in the Fees in Respect of Drugs and Medical Devices Order Submission class Fee as of April 1, 2026 Fee as of April 1, 2027
Section 9 New active substance $616,593 $633,858
Clinical or non-clinical data and chemistry and manufacturing data $319,282 $328,222
Clinical or non-clinical data only $127,668 $131,243
Comparative studies $71,953 $73,968
Chemistry and manufacturing data only $44,269 $45,509
Clinical or non-clinical data only, in support of safety updates to the labelling $23,368 $24,023
Labelling only $6,436 $6,617
Labelling only (generic drugs) $2,419 $2,487
Administrative submission $1,020 $1,049
Disinfectant — full review $13,411 $13,787
Labelling only (disinfectants) $3,015 $3,100
Drug identification number application — labelling standard $1,945 $2,000
Table 2: Fees for examination of a submission — drugs for veterinary use only (Schedule 2)
Section in the Fees in Respect of Drugs and Medical Devices Order Type of submission Component Fee as of April 1, 2026 Fee as of April 1, 2027
Section 21 Application for drug identification number (DIN) Information, other than that referred to in the item below, to support an application for a drug identification number, including the submission of labelling material for a second review, if required $2,946 $3,029
Published references or other data $2,047 $2,105
Documentation to support a change of manufacturer, a change to the name of a manufacturer or a change to the brand name of a drug $1,025 $1,054
Notification — veterinary health product Information contained in a notification filed under subsection C.01.615(1) of the Food and Drug Regulations in respect of a veterinary health product $588 $605
New drug submissions (NDS) Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in one animal species (in the case of an antiparasitic drug, several indications in one food animal species) $65,297 $67,126
Efficacy and safety data (in the intended species) to support a single route of administration and dosage form for an antiparasitic drug in one
non-food animal species
$39,557 $40,665
Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in two animal species, or a single route of administration and dosage form and two indications in one animal species $94,961 $97,620
Efficacy and safety data (in the intended species) to support a growth promotion or production enhancement indication in one animal species $128,589 $132,190
Comparative (pharmacodynamic, clinical or bioavailability) data to support an additional route of administration $11,855 $12,187
Comparative (pharmacodynamic, clinical or bioavailability) data to support each additional strength $1,964 $2,019
For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of 1 000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species $89,035 $91,528
For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of less than 1 000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species $118,700 $122,024
For food-producing animals, residue depletion studies to establish a withdrawal period for an additional dosage form, dosage or route of administration $11,855 $12,187
For food-producing animals (once an acceptable daily intake with a safety factor of 1 000 or less has been established), metabolism and residue depletion studies to establish a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in an additional species $59,332 $60,994
Chemistry and manufacturing data for a
non-compendial medicinal ingredient of a drug
$19,780 $20,334
Chemistry and manufacturing data to support one strength of a single dosage form $19,780 $20,334
Chemistry and manufacturing data to support an additional strength of a single dosage form submitted at the same time as the item above $9,893 $10,171
Documentation to support a change of manufacturer $1,025 $1,054
Supplement to a new drug submission (SNDS) Efficacy data to support an additional indication in one animal species $51,445 $52,886
Efficacy and safety data (in the intended species) to support a single route of administration and dosage form for an antiparasitic drug in one
non-food animal species
$39,557 $40,665
Efficacy and safety data (in the intended species) to support an indication in another animal species $65,297 $67,126
Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in two animal species, or a single route of administration and dosage form and two indications in one animal species $94,961 $97,620
Efficacy and safety data (in the intended species) to support a growth promotion or production enhancement indication in one animal species $128,589 $132,190
Efficacy and safety data (in the intended species) to support the concurrent use of two drugs approved for the same animal species $31,628 $32,514
Comparative (pharmacodynamic, clinical or bioavailability) data to support an additional route of administration $11,855 $12,187
Comparative (pharmacodynamic, clinical or bioavailability) data to support each additional strength $1,964 $2,019
For food-producing animals, residue depletion studies to establish a new withdrawal period for a change in the dosage or route of administration of an approved dosage form in one species $11,855 $12,187
For food-producing animals, metabolism and residue depletion studies to establish a maximum residue limit and a withdrawal period for a single dosage and route of administration of an approved dosage form in an additional species $59,332 $60,994
For food-producing animals, toxicity studies to support a change of an established acceptable daily intake, a maximum residue limit and a withdrawal period $29,667 $30,498
For the concurrent use of two drugs in a species of food-producing animals, residue depletion studies to determine if an extension to existing withdrawal periods is required $23,744 $24,409
Chemistry and manufacturing data to support a change in the source of a medicinal ingredient or its manufacturing process $19,780 $20,334
Chemistry and manufacturing data to support a change in formulation or dosage form $9,893 $10,171
Chemistry and manufacturing data to support a change in the packaging or sterilization process $7,888 $8,109
Chemistry and manufacturing data to support an extension of the expiry date $5,930 $6,097
Chemistry and manufacturing data to support the concurrent use of two drugs $5,930 $6,097
Chemistry and manufacturing data to support a change in the manufacturing site for parenteral dosage form $1,964 $2,019
Documentation to support a change to the brand name of a drug $1,025 $1,054
Abbreviated new drug submission (ANDS) or supplement to an abbreviated new drug submission (SANDS) Comparative (pharmacodynamic, clinical or bioavailability) data to support a single route of administration and dosage form $11,855 $12,187
For food-producing animals, residue depletion studies to confirm that the withdrawal periods for each species fall within the conditions of use for the Canadian reference product $11,855 $12,187
Chemistry and manufacturing data for a
non-compendial medicinal ingredient of a drug
$19,780 $20,334
Chemistry and manufacturing data to support a single dosage form $19,780 $20,334
Documentation to support

(a) a change of manufacturer, in the case of an abbreviated new drug submission;

or

(b) a change to the brand name of a drug, in the case of a supplement to an abbreviated new drug submission

$1,025 $1,054
Preclinical submission Efficacy and safety data (in the intended species) and protocol to support the conduct of clinical studies relative to a single dosage form, route of administration and indication in one species $19,780 $20,334
Efficacy data and protocol to support the conduct of clinical studies relative to a single route of administration and indication with a dosage form for which a notice of compliance has been issued for use in the species to be treated $15,816 $16,259
For food-producing animals, toxicity, metabolism and residue depletion studies to establish a temporary acceptable daily intake, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species $59,332 $60,994
For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of 1 000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species $89,035 $91,528
For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of less than 1 000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species $118,700 $122,024
For food-producing animals (once an acceptable daily intake with a safety factor of 1 000 or less has been established), metabolism studies to establish a withdrawal period for a single dosage form, dosage and route of administration in an additional species $29,667 $30,498
Chemistry and manufacturing data to support a single dosage form containing a non-compendial medicinal ingredient $19,780 $20,334
Chemistry and manufacturing data to support a single dosage form containing a compendial medicinal ingredient $9,893 $10,171
Sale of new drug for emergency treatment Information and material to support the sale of a new drug to be used in the emergency treatment of a non-food-producing animal $64 $66
Information and material to support the sale of a new drug to be used in the emergency treatment of a food-producing animal $127 $131
Experimental studies certificate Information and material to support the issuance of an experimental studies certificate for a drug to be administered to a non-food-producing animal $1,181 $1,215
Information and material to support the issuance of an experimental studies certificate whose protocol is the same as that of a previously authorized experimental studies certificate for a drug to be administered to a non-food-producing animal $592 $609
Information and material to support the issuance of an experimental studies certificate for a drug to be administered to a food-producing animal $3,558 $3,658
Information and material to support the issuance of an experimental studies certificate whose protocol is the same as that of a previously authorized experimental studies certificate for a drug to be administered to a food-producing animal $592 $609
Notifiable change or protocol review Information and material to support an application for a notifiable change $5,316 $5,465
A protocol that is filed with the Minister and may support a new drug submission, an abbreviated new drug submission, a supplement to a new drug submission or abbreviated new drug submission, a preclinical submission or information and material that is filed for the purpose of obtaining an experimental studies certificate $5,316 $5,465
Table 3: Fees for examination of an application for an establishment licence — drugs for human use (Schedule 3)
Section in the Fees in Respect of Drugs and Medical Devices Order Activity Fee as of April 1, 2026 Fee as of April 1, 2027
Sections 33 and 41 Fabrication — sterile dosage form $50,401 $51,813
Sections 34 and 42 Importation $38,916 $40,006
Sections 35 and 43 Fabrication — non-sterile dosage form $37,365 $38,412
Sections 36 and 44 Distribution $19,864 $20,421
Sections 37 and 45 Wholesaling $11,592 $11,917
Sections 38 and 46 Packaging/labelling $7,286 $7,491
Sections 39 and 47 Testing $6,014 $6,183
Section 40 Foreign site (each) $1,107 $1,138
Table 4: Fees for examination of an application for an establishment licence — drugs for veterinary use only (Schedule 4)
Section in the Fees in Respect of Drugs and Medical Devices Order Activity Fee as of April 1, 2026 Fee as of April 1, 2027
Sections 33 and 41 Fabrication — sterile dosage form $50,401 $51,813
Sections 34 and 42 Importation $38,916 $40,006
Sections 35 and 43 Fabrication — non-sterile dosage form $37,365 $38,412
Sections 36 and 44 Distribution $19,864 $20,421
Sections 37 and 45 Wholesaling $8,864 $9,113
Sections 38 and 46 Packaging/labelling $7,286 $7,491
Sections 39 and 47 Testing $6,014 $6,183
Section 40 Foreign site (each) $1,107 $1,138
Table 5: Fees for right to sell drugs for human use (Schedule 6)
Section in the Fees in Respect of Drugs and Medical Devices Order Type of drug Fee as of April 1, 2026 Fee as of April 1, 2027
Section 52 Disinfectant $1,760 $1,810
Non-prescription $3,391 $3,486
Drug other than one referred to in item 1 or 2 (above) $5,626 $5,784
Table 6: Fees for right to sell drugs for veterinary use only (Schedule 7)
Section in the Fees in Respect of Drugs and Medical Devices Order Type of drug Fee as of April 1, 2026 Fee as of April 1, 2027
Section 56 Veterinary drug $577 $594

Part 3 — Medical devices

Table 7: Fees for examination of an application for a medical device licence (Schedule 8)
Section in the Fees in Respect of Drugs and Medical Devices Order Category Fee as of April 1, 2026 Fee as of April 1, 2027
Section 60 Applications for Class II licence $643 $662
Applications for Class II licence amendment $331 $341
Applications for Class III licence $14,163 $14,560
Applications for Class III licence (near patient) $30,169 $31,014
Applications for Class III licence amendment — changes in manufacturing $4,470 $4,596
Applications for Class III licence amendment — significant changes not related to manufacturing $11,369 $11,688
Applications for Class IV licence $30,713 $31,573
Applications for Class IV licence amendment — changes in manufacturing $4,470 $4,596
Applications for Class IV licence amendment — significant changes not related to manufacturing $16,251 $16,707
Applications for Class II, III or Class IV licence or licence amendment — private label medical device $179 $185
Table 8: Fees for examination of an application for an establishment licence — medical devices
Section in the Fees in Respect of Drugs and Medical Devices Order Fee category Fee as of April 1, 2026 Fee as of April 1, 2027
Section 71 Medical device $5,519 $5,674
Table 9: Fees for right to sell licensed Class II, III or IV medical devices
Section in the Fees in Respect of Drugs and Medical Devices Order Fee category Fee as of April 1, 2026 Fee as of April 1, 2027
Section 77 Medical device $460 $473
Table 10: Fees for the examination of a biocide application (Schedule 2.1)
Section in the Fees in Respect of Drugs and Medical Devices Order Fee category Fees as of May 31, 2026 Fees as of April 1, 2027
Section 27 Biocide full review — novel biocide $42,394 $43,582
Biocide full review — tier I $8,742 $8,987
Biocide full review — tier II $11,664 $11,991
Biocide full review — tier III $13,753 $14,139
Biocide comparison — labelling only $2,795 $2,874
Biocide comparison — administrative application $992 $1,020
Biocide — use of foreign decisions $3,153 $3,242
Biocide monograph $1,893 $1,947
Biocide major change — monograph $1,387 $1,426
Biocide major change — quality and risks $5,040 $5,182
Biocide minor change $1,387 $1,426
Table 11: Fees for the right to sell biocides
Section in the Fees in Respect of Drugs and Medical Devices Order Type of drug Fee as of May 31, 2026 Fee as of April 1, 2027
Section 58 Biocide $1,562 $1,606

DEPARTMENT OF HEALTH

PATENT ACT

Notice of annual increase of fee pursuant to the Certificate of Supplementary Protection Regulations

Notice is hereby given that, in keeping with subsection 9(1) of the Certificate of Supplementary Protection Regulations, the fee will increase by the annual 2% amount, rounded up to the nearest dollar.

The current fee and the fee updated as of April 1, 2027, are listed below.

Any inquiries or comments about the updated fee can be directed to Rosslynn Miller-Lee, Director General, Business Facilitation and Modernization Directorate, Health Products and Food Branch, 613‑327‑0798 (telephone) or cro-brc@hc-sc.gc.ca (email).

Table: Annual increase of fee pursuant to Certificate of Supplementary Protection Regulations
Type of certificate Subsection in Certificate of Supplementary Protection Regulations Fee as of April 1, 2026 Fee as of April 1, 2027
Certificate of Supplementary Protection 9(1) $10,776 $10,992

PRIVY COUNCIL OFFICE

Appointment opportunities

The Government of Canada is committed to appointing highly qualified individuals to Governor in Council positions through competency-based assessments. Governor in Council appointments are guided by principles of competency, transparency and respect for diversity. These principles ensure appointees are held to the high standards of professionalism, responsibility, and ethical behaviour. High quality and timely appointments ensure that the Government carries out its mandate and achieves its objectives in an efficient manner.

The Government of Canada is currently seeking applications from Canadians across the country who are interested in the following positions.

Current opportunities

The following opportunities for appointments to Governor in Council positions are currently open for applications. Every opportunity is open for a minimum of two weeks from the date of posting on the Governor in Council appointments website.

Governor in Council appointment opportunities
Position Organization Closing date
President and Chief Executive Officer Atomic Energy of Canada Limited November 19, 2026
Director Canadian Tourism Commission December 7, 2026
Member Immigration and Refugee Board November 26, 2026
Governor International Development Research Centre December 10, 2026
Member — All Divisions Parole Board of Canada November 24, 2026
Vice-Chairperson Social Security Tribunal of Canada November 26, 2026